(Reuters) – Novo A/S, the parent company behind the world’s largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month.
Kolding, 56, has previously served as chief executive of Denmark’s largest bank, Danske Bank, and the world’s largest container shipping company, Maersk Line. He has been in the Novo job less than two years.
Aside from its shares in Novo Nordisk and top industrial enzyme maker Novozymes, Novo A/S has billions invested in both Danish and international life science companies.
“The board has concluded that having a CEO with a different profile to that of Eivind Kolding will be required in the long term,” chairman of the board Steen Scheibye said.
Novo said the hunt for a replacement has begun, but gave no further details. Scheibye becomes acting chief executive when Kolding leaves. ($1 = 6.6383 Danish crowns) (Reporting by Annabella Pultz Nielsen; Editing by Greg Mahlich)
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
